References:
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri
H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS,
Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T,
Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A,
Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC,
Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group.
2021 ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi:
10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14;:
PMID: 34447992.
- Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, Lam CS,
Heerspink HL, Khunti K. Outcome trends in people with heart failure,
type 2 diabetes mellitus and chronic kidney disease in the UK over
twenty years. EClinicalMedicine. 2021 Feb 4;32:100739. doi:
10.1016/j.eclinm.2021.100739. PMID: 33688855; PMCID: PMC7910705.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM,
Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow
GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS,
Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR,
Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart
Failure: A Report of the American College of Cardiology/American Heart
Association Joint Committee on Clinical Practice Guidelines.
Circulation. 2022 May 3;145(18):e895-e1032. doi:
10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in:
Circulation. 2022 May 3;145(18):e1033. PMID: 35363499.
- Deedwania P, Acharya T. Cardiovascular Protection with
Anti-hyperglycemic Agents. Am J Cardiovasc Drugs. 2019
Jun;19(3):249-257. doi: 10.1007/s40256-019-00325-9. PMID: 30767126.
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A,
Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and
FIGARO-DKD investigators. Cardiovascular and kidney outcomes with
finerenone in patients with type 2 diabetes and chronic kidney
disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb
10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Erratum in: Eur
Heart J. 2022 May 21;43(20):1989. PMID: 35023547; PMCID: PMC8830527.
- Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic
Kidney Disease: Current and Future. Diabetes Metab J. 2021
Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22. PMID:
33508907; PMCID: PMC7850867.
- Rossing P. Clinical perspective-evolving evidence of mineralocorticoid
receptor antagonists in patients with chronic kidney disease and type
2 diabetes. Kidney Int Suppl (2011). 2022 Apr;12(1):27-35. doi:
10.1016/j.kisu.2021.11.005. Epub 2022 Mar 18. PMID: 35529090; PMCID:
PMC9073226.
- Epstein M. Considerations for the future: current and future treatment
paradigms with mineralocorticoid receptor antagonists-unmet needs and
underserved patient cohorts. Kidney Int Suppl (2011). 2022
Apr;12(1):69-75. doi: 10.1016/j.kisu.2021.11.008. Epub 2022 Mar 18.
PMID: 35529085; PMCID: PMC9073253.
- Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F.
Mineralocorticoid receptor antagonists in diabetic kidney disease -
mechanistic and therapeutic effects. Nat Rev Nephrol. 2022
Jan;18(1):56-70. doi: 10.1038/s41581-021-00490-8. Epub 2021 Oct 21.
PMID: 34675379.
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P,
Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD
Investigators. Cardiovascular Events with Finerenone in Kidney Disease
and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi:
10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement
for reporting systematic reviews and meta-analyses of studies that
evaluate healthcare interventions: explanation and elaboration. BMJ.
2009 Jul 21;339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID:
PMC2714672
12.Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic
J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group;
Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool
for assessing risk of bias in randomised trials. BMJ. 2011 Oct
18;343:d5928. doi: 10.1136/bmj.d5928. PMID: 22008217; PMCID:
PMC3196245
13. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H,
Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A,
Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid
Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN)
Study Group. Effect of Finerenone on Albuminuria in Patients With
Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep
1;314(9):884-94. doi: 10.1001/jama.2015.10081. PMID: 26325557.
14.Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof
P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD
Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes
in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi:
10.1056/NEJMoa2025845. Epub 2020 Oct 23. PMID: 33264825.
15.Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P,
Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD
Investigators. Finerenone and Cardiovascular Outcomes in Patients With
Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb
9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020
Nov 16. PMID: 33198491; PMCID: PMC7864612.
16.Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL,
Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD
Investigators. Finerenone Reduces Risk of Incident Heart Failure in
Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses
From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447.
doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13. PMID:
34775784; PMCID: PMC8812430.
- Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, Nowack
C, Kolkhof P, Yamasaki Y; ARTS-DN Japan study group. A randomized
controlled study of finerenone versus placebo in Japanese patients
with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes
Complications. 2017 Apr;31(4):758-765. doi:
10.1016/j.jdiacomp.2016.11.021. Epub 2016 Dec 14. PMID: 28025025.
- Redon J. New insights of cardiovascular and renal protection in
diabetic chronic kidney disease with finerenone. Cardiovasc Res. 2022
Mar 25;118(5):e36-e37. doi: 10.1093/cvr/cvac024. PMID: 35333317.
- Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA. Finerenone
: third-generation mineralocorticoid receptor antagonist for the
treatment of heart failure and diabetic kidney disease. Expert Opin
Investig Drugs. 2015;24(8):1123-35. doi:
10.1517/13543784.2015.1059819. Epub 2015 Jun 20. PMID: 26095025.
- Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin
Exp Nephrol. 2008 Aug;12(4):233-242. doi: 10.1007/s10157-008-0034-9.
Epub 2008 Mar 5. PMID: 18317876.
- Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y,
Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K,
Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and
mineralocorticoid receptors in rat mesangial cell proliferation and
deformability. Hypertension. 2005 Apr;45(4):710-6. doi:
10.1161/01.HYP.0000154681.38944.9a. Epub 2005 Feb 7. PMID: 15699469.
- Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor
antagonist for the treatment of chronic kidney disease associated with
type 2 diabetes. Expert Rev Clin Pharmacol. 2022 May;15(5):501-513.
doi: 10.1080/17512433.2022.2094770. Epub 2022 Jul 3. PMID: 35762406.
- Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE.
Non-steroidal mineralocorticoid receptor antagonism for the treatment
of cardiovascular and renal disease. Eur J Heart Fail. 2017
Jun;19(6):811. doi: 10.1002/ejhf.888. Erratum for: Eur J Heart Fail.
2016 Jan;18(1):28-37. PMID: 28586538.
- Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H,
Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C,
Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A
randomized controlled study of finerenone vs. eplerenone in patients
with worsening chronic heart failure and diabetes mellitus and/or
chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi:
10.1093/eurheartj/ehw132. Epub 2016 Apr 29. PMID: 27130705; PMCID:
PMC4946749.
- Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS.
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of
Finerenone. Curr Cardiol Rep. 2020 Sep 10;22(11):140. doi:
10.1007/s11886-020-01399-7. PMID: 32910349.
- Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel
non-steroidal mineralocorticoid receptor antagonist finerenone for the
treatment of chronic heart failure: A systematic review and
meta-analysis. Medicine (Baltimore). 2018 Apr;97(16):e0254. doi:
10.1097/MD.0000000000010254. PMID: 29668577; PMCID: PMC5916685.
- Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S,
Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J.
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects
Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of
Oxidative Stress. Hypertension. 2017 May;69(5):870-878. doi:
10.1161/HYPERTENSIONAHA.116.08526. Epub 2017 Mar 20. PMID: 28320854.